THE IMPACT OF GENERIC DRUG ENTRY ON MARKET SHARES AND PRICES OF BRAND-NAME DRUGS-EVIDENCE FROM CHINESE PHARMACEUTICAL MARKET

被引：2

作者：

Chen, J. ^{[1
]}

Tian, Y. ^{[1
]}

Shi, L. W. ^{[1
]}

机构：

[1] Peking Univ, Sch Pharmaceut Sci, Beijing, Peoples R China

来源：

VALUE IN HEALTH | 2018年 / 21卷

关键词：

D O I：

10.1016/j.jval.2018.07.065

中图分类号：

F [经济];

学科分类号：

02 ;

摘要：

PR2

引用

页码：S9 / S9

页数：1

共 50 条

[1] The impact of generic drug competition on brand name market shares - Evidence from micro data
Aronsson, T
Bergman, MA
Rudholm, N
REVIEW OF INDUSTRIAL ORGANIZATION, 2001, 19 (04) : 425 - 435
[2] The Impact of Generic Drug Competition on Brand Name Market Shares – Evidence from Micro Data
Thomas Aronsson
Mats A. Bergman
Niklas Rudholm
Review of Industrial Organization, 2001, 19 (4) : 423 - 433
[3] Choice of Generic versus Brand-Name Antidepressants in a Regulated Prescription Drug Market: Evidence from Taiwan
Liu, Ya-Ming
Ou, Huang-Tz
Yang, Yen-Kuang
JOURNAL OF MENTAL HEALTH POLICY AND ECONOMICS, 2014, 17 (04): : 163 - 172
[4] A drug by any other name ... generic and brand-name drugs are clinically equivalent
Morgan, Steven G.
JOURNAL OF PRIMARY HEALTH CARE, 2015, 7 (02) : 93 - 93
[5] Economic Impact of Switchback from Generic to Brand-Name Drugs: Example of Allopurinol
Laroche, M. L.
Crepin, S.
Deysson, M.
Merle, L.
DRUG SAFETY, 2009, 32 (10) : 905 - 905
[6] Generic and brand-name drugs. Are different criteria sufficiently taken into account before granting market authorisation?
Laroche, ML
Merle, L
ACTA CLINICA BELGICA, 2006, 61 : 48 - 50
[7] Brand Loyalty and Generic Entry: Why Do Brand-Name Drug Companies Launch Their Own Generics?
Yunyun Wan
The Japanese Economic Review, 2018, 69 : 340 - 346
[8] Brand Loyalty and Generic Entry: Why do Brand-Name Drug Companies Launch Their Own Generics?
Wan, Yunyun
JAPANESE ECONOMIC REVIEW, 2018, 69 (03) : 340 - 346
[9] Reasons for switching from a generic to a brand-name drug:: example of allopurinol
Laroche, M. L.
Crepin, S.
Rolland, G.
Merle, L.
FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2008, 22 : 22 - 22
[10] Marketing Status and Brand-Name Drug Prices: Evidence From Rx-To-OTC Switch
Lin, Lin
Wang, Bo
HEALTH ECONOMICS, 2025,

← 1 2 3 4 5 →